



1645

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.: 10/527,771
Applicant: Claerebout *et al.*
U.S.C. 371 Filing Date: March 11, 2005
International File Date: September 11, 2003
Group Art Unit: 1645
Examiner: Gangle, B.
For: Ostertagia Vaccine
Attorney Docket: I-2002.015 US

February 8, 2006

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR 1.97(b)

Mail Stop: Amendment
Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir/Madam:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-SB-08B. One copy of each of these documents is attached.

This Information Disclosure Statement is being submitted before a first office action on the merits. Accordingly, payment of a fee is not required.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. It is respectfully requested that the information be considered during the prosecution of this application and that the cited documents be listed on the front page of any patent issuing from this application.

Applicants are providing herewith a copy of an abstract submitted for and slides presented at the Novel Approaches Meeting III at the Moredun Research Institute from July 2-5, 2002. The title of the presentation was "Identification of protective antigens of Ostertagia


Appl. No 10/527,771
Information Disclosure Statement
Attorney Docket No. I-2002.015 US
February 8, 2006
ostertagi.”

Applicants have provided what are currently believed to be the correct dates of the documents. However, Applicants reserve the right to demonstrate that the documents were not published or presented on the dates indicated.

Applicants do not believe that any other fee is due in connection with this filing. If, however, Applicants do owe any such fee(s), the Commissioner is hereby authorized to charge the fee(s) to Deposit Account No. **02-2334**. In addition, if there is ever any other fee deficiency or overpayment under 37 C.F.R. §1.16 or 1.17 in connection with this patent application, the Commissioner is hereby authorized to charge such deficiency or overpayment to Deposit Account No. **02-2334**.


Applicants submit that this application is in condition for allowance, and request that it be allowed. The Examiner is requested to call the Undersigned if any issues arise that can be addressed over the phone to expedite examination of this application.

Respectfully submitted,

A handwritten signature in dark ink, appearing to read 'ALS', is written over a horizontal line.

Aaron L. Schwartz,
Reg. No. 48,181
Attorney for Applicants
Patent Department
Intervet Inc.
P.O. Box 318
29160 Intervet Lane
Millsboro, DE 19966
302-933-4034
(302) 934-4305 (fax)

ALS:dap



PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/527,771
Filing Date	March 11, 2005 (U.S.C. 371)
First Named Inventor	CLAEREBOUT, et al.
Art Unit	1645
Examiner Name	Brian J. Gangle
Attorney Docket Number	I-2002.015 US

Sheet 1

of

1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Abstract submitted and slides presented during an oral presentation "Identification of protective antigens of Ostertagia ostertagi" Moredun Research Inst. (July 2-5, 2002)	
		VERCAUTEREN, et al. "Isolation and Identification of In Vitro Released Excretory-Secretory Products of..." 05/04/01, Proceedings of meeting of Belgian Society for Parasitology	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO:**

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on February 8, 2006.
Date



Signature

Diane Payne
Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Applicant: CLAEREBOU *et al.*
Serial No: 10/527,771
Customer No.: 31846
Attorney Docket: I-2002.015 US

Receipt acknowledged of the following documents in the above-identified application:

Information Disclosure Statement (2 pages)
IDS PTO Form PTO SB08B (1 page)
Cited References (2 references)
Self-addressed stamped postcard (1)